Thomas Illmer

Dresden, SN, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.

Journal: Leukemia & lymphoma

Published: March 17, 2026

Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.

Digital Surveillance After Allogeneic Hematopoietic Stem Cell Transplantation Guides Therapeutic Interventions to Reduce Non-Relapse Mortality.

Journal: European journal of haematology

Published: December 17, 2025

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

Journal: European journal of haematology

Published: December 12, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: December 08, 2025

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Journal: Leukemia

Published: October 28, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

Uncovering gaps in personalised lung cancer care in Germany: a white spot analysis.

Uncovering gaps in personalised lung cancer care in Germany: a white spot analysis.

Journal: BMC cancer

Published: July 06, 2025

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo-Controlled Phase 2 DELTA Trial.

Journal: American journal of hematology

Published: June 25, 2025

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Journal: Blood

Published: February 24, 2025

Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.

Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.

Journal: MedComm

Published: October 19, 2024

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 30, 2024

Showing 1-12 of 48

Last Updated: 09/26/2026